TGTX Tg Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TGTX

Price (delayed)

$16.19

Market cap

$2.5B

P/E Ratio

179.89

Dividend/share

N/A

EPS

$0.09

Enterprise value

$2.52B

TG Therapeutics is a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. In addition to an active ...

Highlights
The company's net income has surged by 149% QoQ and by 106% YoY
Tg Therapeutics's EPS has surged by 145% QoQ and by 106% YoY
The equity has surged by 174% year-on-year but it has declined by 2.6% since the previous quarter
The gross margin has increased by 3.9% YoY but it has decreased by 2.8% QoQ
TGTX's debt is up by 34% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.tgtherapeutics.com
Peers: ALKS ALIM NERV

Key stats

What are the main financial stats of TGTX
Market
Shares outstanding
154.42M
Market cap
$2.5B
Enterprise value
$2.52B
Valuations
Price to earnings (P/E)
179.89
Price to book (P/B)
15.27
Price to sales (P/S)
9.84
EV/EBIT
97.96
EV/EBITDA
97.16
EV/Sales
10.76
Earnings
Revenue
$233.66M
EBIT
$25.68M
EBITDA
$25.89M
Free cash flow
-$31.41M
Per share
EPS
$0.09
Free cash flow per share
-$0.22
Book value per share
$1.06
Revenue per share
$1.65
TBVPS
$2.32
Balance sheet
Total assets
$329.59M
Total liabilities
$169.09M
Debt
$109.35M
Equity
$160.5M
Working capital
$264.22M
Liquidity
Debt to equity
0.68
Current ratio
5.92
Quick ratio
5.02
Net debt/EBITDA
0.58
Margins
EBITDA margin
11.1%
Gross margin
94%
Net margin
5.4%
Operating margin
8.8%
Efficiency
Return on assets
4.7%
Return on equity
12.9%
Return on invested capital
12%
Return on capital employed
9.3%
Return on sales
11%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TGTX stock price

How has the Tg Therapeutics stock price performed over time
Intraday
-1.4%
1 week
20.19%
1 month
11.89%
1 year
-53.57%
YTD
-5.21%
QTD
6.44%

Financial performance

How have Tg Therapeutics's revenue and profit performed over time
Revenue
$233.66M
Gross profit
$219.53M
Operating income
$20.63M
Net income
$12.67M
Gross margin
94%
Net margin
5.4%
Tg Therapeutics's operating margin has surged by 188% QoQ and by 100% YoY
The company's net income has surged by 149% QoQ and by 106% YoY
TGTX's net margin has soared by 139% QoQ and by 100% YoY
The operating income has soared by 111% YoY

Growth

What is Tg Therapeutics's growth rate over time

Valuation

What is Tg Therapeutics stock price valuation
P/E
179.89
P/B
15.27
P/S
9.84
EV/EBIT
97.96
EV/EBITDA
97.16
EV/Sales
10.76
Tg Therapeutics's EPS has surged by 145% QoQ and by 106% YoY
The equity has surged by 174% year-on-year but it has declined by 2.6% since the previous quarter
The P/B is 69% below the last 4 quarters average of 48.9 and 40% below the 5-year quarterly average of 25.6
The P/S is 100% below the 5-year quarterly average of 5698.9 and 90% below the last 4 quarters average of 102.3
The revenue rose by 23% QoQ

Efficiency

How efficient is Tg Therapeutics business performance
The ROA has soared by 143% from the previous quarter and by 106% YoY
The company's return on equity has surged by 136% QoQ and by 107% YoY
TGTX's ROIC has soared by 109% YoY
Tg Therapeutics's return on sales has surged by 100% YoY

Dividends

What is TGTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TGTX.

Financial health

How did Tg Therapeutics financials performed over time
The total assets is 95% higher than the total liabilities
TGTX's current ratio has soared by 87% year-on-year and by 7% since the previous quarter
The total assets has soared by 70% YoY
TGTX's debt is 32% lower than its equity
The equity has surged by 174% year-on-year but it has declined by 2.6% since the previous quarter
The debt to equity has plunged by 51% YoY but it has grown by 3% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.